Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25321066 | 0.82 | CYP19A1 (0.34) | CYP19A1PDK2 | |
| SCHEMBL26022218 | 0.80 | TDP1 (0.41) | EPHX2TDP1MAPK1MMP3CNR1 | |
| SCHEMBL25316861 | 0.76 | TAAR1 (0.39) | CYP19A1 | |
| SCHEMBL25902816 | 0.73 | GPR119 (0.47) | EPHX2TDP1MAPK1MMP3TP53 | |
| SCHEMBL25315858 | 0.72 | CYP19A1 (0.34) | TP53SMN1; SMN2CYP19A1HTT | |
| SCHEMBL25903076 | 0.71 | MAPK1 (0.47) | EPHX2TDP1MAPK1CNR1CNR2 | |
| SCHEMBL21340057 | 0.70 | TDP1 (0.50) | EPHX2TDP1MAPK1CNR1CNR2 | |
| SCHEMBL25903065 | 0.69 | TDP1 (0.42) | EPHX2TDP1MAPK1MMP3CNR1 | |
| SCHEMBL21218072 | 0.68 | TDP1 (0.49) | EPHX2TDP1MAPK1TP53SMN1; SMN2 | |
| SCHEMBL26022176 | 0.68 | MAPK1 (0.48) | EPHX2TDP1MAPK1L3MBTL1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | EPHX2 2977/4885TDP1 761/4885MAPK1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.